United Therapeutics wins Delaware ruling that Liquidia infringes treprostinil PH-ILD patent claims

Bitget2026/09/30 23:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

United Therapeutics won a Delaware federal court ruling that Liquidia’s Yutrepia infringed two claims of its U.S. Patent No. 11,826,327.
Decision covered Yutrepia’s PH-ILD use; court rejected Liquidia’s bid to invalidate the claims.
Company plans to seek an order directing the FDA to withdraw Yutrepia’s NDA approval, potentially removing it until labeling drops PH-ILD.
United Therapeutics also intends to pursue monetary damages for past infringement, including a possible royalty on Yutrepia sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930122219) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

United Therapeutics wins Delaware ruling that Liquidia infringes treprostinil PH-ILD patent claims

You may also like

Crypto prices